Shudong F. Wang

University Park
Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Abstracts of the 36th World Congress on Ultrasound in Obstetrics and Gynecology, 4-7 September 2026, London, UK.

Journal: Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Published: July 06, 2026

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 19, 2026

Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.

Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.

Journal: Journal of hematology & oncology

Published: February 03, 2026

A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.

A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 05, 2025

Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition.

Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: May 02, 2025

A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer.

A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer.

Journal: Investigational new drugs

Published: April 10, 2025

Targeting CDK2 to combat drug resistance in cancer therapy.

Targeting CDK2 to combat drug resistance in cancer therapy.

Journal: Future oncology (London, England)

Published: October 29, 2024

Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Journal: British journal of cancer

Published: October 25, 2024

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.

Journal: Cancer medicine

Published: May 21, 2024

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Journal: British journal of cancer

Published: October 26, 2023

Selective inhibition of CDK9 in triple negative breast cancer.

Selective inhibition of CDK9 in triple negative breast cancer.

Journal: Oncogene

Published: March 24, 2023

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Journal: Molecules (Basel, Switzerland)

Published: March 03, 2023

Showing 1-12 of 90

Last Updated: 09/26/2026